Symbols

TBPH

Theravance·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Stock Price Surged Significantly

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

RSI Overbought

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TBPH

Theravance Biopharma, Inc.

A biopharmaceutical company that developing small molecule medicines in the areas of infections, CNS/pain, respiratory disease

Industry

Pharmaceutical

Established Date

Listing Date

05/16/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.theravance.com

Security Type

Common stock

Office address

901 Gateway Boulevard South San Francisco CA 94080

Business

Introduction

Theravance Biopharma, Inc., was registered as a Cayman Islands exempted company limited by shares in July 2013. The company is a biopharmaceutical company focused on drug discovery, development and commercialization. The company's core purpose is to create drugs that can change people's lives. The company used decades of expertise to develop the FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease.

Company Financials

EPS

TBPH has released its 2025 Q4 earnings. EPS was reported at 1.15, versus the expected 1, beating expectations. The chart below visualizes how TBPH has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TBPH has released its 2025 Q4 earnings report, with revenue of 45.89M, reflecting a YoY change of 144.70%, and net profit of 61.02M, showing a YoY change of 493.02%. The Sankey diagram below clearly presents TBPH's revenue sources and cost distribution.